Rong Shi

Previously Director of Quantitative Clinical Pharmacology at Daiichi-Sankyo, led cross functional team (clinical pharmacology, pharmacometrics, bioanalytical science, DMPK, and toxicology) to support the most recent FDA BTD Patritumab Deruxtecan; Clinical Pharmacology Lead at Genentech/Roche, and Bristol Myers Squibb to support the development of more than 15 assets in early & late phase, post marketing development, and the global approval of anti-CD79b ADC Polivy.